Published in Exp Ther Med on January 20, 2011
Absolute quantification of DcR3 and GDF15 from human serum by LC-ESI MS. J Cell Mol Med (2015) 0.75
A case-control study about the association between vascular endothelial growth inhibitor gene polymorphisms and breast cancer risk in female patients in Northeast China. Chin J Cancer Res (2016) 0.75
Knockdown of Decoy Receptor 3 Impairs Growth and Invasiveness of Hepatocellular Carcinoma Cell Line of HepG2. Chin Med J (Engl) (2016) 0.75
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell (2001) 12.59
The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell (1991) 10.96
Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell (1993) 9.06
A novel domain within the 55 kd TNF receptor signals cell death. Cell (1993) 5.59
Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J (1995) 5.59
Selectins: interpreters of cell-specific carbohydrate information during inflammation. Science (1992) 4.75
LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity (1998) 4.23
Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol (2004) 3.95
TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity (2002) 3.46
Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature (1998) 2.98
Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science (1996) 2.87
Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity (2004) 2.36
LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol (2000) 2.27
A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem (1999) 1.98
A death-domain-containing receptor that mediates apoptosis. Nature (1996) 1.92
The E-selectin-ligand ESL-1 is a variant of a receptor for fibroblast growth factor. Nature (1995) 1.83
The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol (1998) 1.78
TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95). Immunity (1997) 1.74
Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B. Curr Biol (1996) 1.72
Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci U S A (2000) 1.67
Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth. J Biol Chem (1998) 1.60
Decoy receptor 3 expression in AsPC-1 human pancreatic adenocarcinoma cells via the phosphatidylinositol 3-kinase-, Akt-, and NF-kappa B-dependent pathway. J Immunol (2008) 1.60
LARD: a new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing. Proc Natl Acad Sci U S A (1997) 1.58
Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res (2001) 1.58
The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells. J Immunol (2007) 1.56
Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. Gynecol Oncol (2007) 1.46
Divergent fates of P- and E-selectins after their expression on the plasma membrane. Mol Biol Cell (1993) 1.45
TL1A-induced NF-kappaB activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1 cells. J Biol Chem (2003) 1.40
Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. Int J Cancer (2003) 1.40
The role of FasL-induced apoptosis in immune privilege. Immunol Today (1997) 1.39
Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia (2008) 1.33
Multiple pathways of TWEAK-induced cell death. J Immunol (2002) 1.32
Role of Fas-mediated cell death in the regulation of immune responses. Curr Opin Immunol (1996) 1.31
VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J (1999) 1.29
TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages. J Immunol (2000) 1.27
High DcR3 expression predicts stage pN2-3 in gastric cancer. Am J Clin Oncol (2008) 1.24
Modulation of dendritic cell differentiation and maturation by decoy receptor 3. J Immunol (2002) 1.20
Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. J Pathol (1998) 1.18
High DcR3 expression predicts stage pN2 in gastric cancer. Hepatogastroenterology (2008) 1.18
Modulation of T-cell responses to alloantigens by TR6/DcR3. J Clin Invest (2001) 1.16
Modulation of macrophage differentiation and activation by decoy receptor 3. J Leukoc Biol (2003) 1.15
Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action. Cancer Res (2004) 1.14
Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis. Arthritis Rheum (2007) 1.13
Expression of the lymphotoxin beta receptor on follicular stromal cells in human lymphoid tissues. Cell Death Differ (1998) 1.13
Expression and function of TNF-family proteins and receptors in human osteoblasts. Bone (2003) 1.12
Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily. Int J Cancer (1999) 1.11
A novel secreted splice variant of vascular endothelial cell growth inhibitor. FASEB J (2002) 1.10
FasL:Fas ratio--a prognostic factor in breast carcinomas. Cancer Res (2000) 1.10
Expression of decoy receptor 3 in liver tissue microarrays. Natl Med J India (2009) 1.09
Death receptor-3, a new E-Selectin counter-receptor that confers migration and survival advantages to colon carcinoma cells by triggering p38 and ERK MAPK activation. Cancer Res (2006) 1.07
DcR3 and survivin are highly expressed in colorectal carcinoma and closely correlated to its clinicopathologic parameters. J Zhejiang Univ Sci B (2009) 1.06
Attenuation of Th1 response in decoy receptor 3 transgenic mice. J Immunol (2005) 1.06
Genomic structure, expression, and chromosome mapping of the mouse homologue for the WSL-1 (DR3, Apo3, TRAMP, LARD, TR3, TNFRSF12) gene. Immunogenetics (2001) 1.04
Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis. World J Gastroenterol (2005) 1.03
Fisetin, a natural flavonoid, targets chemoresistant human pancreatic cancer AsPC-1 cells through DR3-mediated inhibition of NF-kappaB. Int J Cancer (2009) 1.03
Over-expression of decoy receptor 3 in gastric precancerous lesions and carcinoma. Ups J Med Sci (2008) 1.01
Lymphotoxin-beta receptor activation by activated T cells induces cytokine release from mouse bone marrow-derived mast cells. J Immunol (2004) 1.00
VEGI, a new member of the TNF family activates nuclear factor-kappa B and c-Jun N-terminal kinase and modulates cell growth. Oncogene (1999) 1.00
Death decoy receptor TR6/DcR3 inhibits T cell chemotaxis in vitro and in vivo. J Immunol (2003) 1.00
Studies on the interaction between TWEAK and the death receptor WSL-1/TRAMP (DR3). FEBS Lett (2000) 0.97
Inhibition of endothelial progenitor cell differentiation by VEGI. Blood (2009) 0.97
Enhanced adhesion of monocytes via reverse signaling triggered by decoy receptor 3. Exp Cell Res (2004) 0.95
A new death receptor 3 isoform: expression in human lymphoid cell lines and non-Hodgkin's lymphomas. Biochem Biophys Res Commun (1998) 0.94
Decoy receptor 3, upregulated by Epstein-Barr virus latent membrane protein 1, enhances nasopharyngeal carcinoma cell migration and invasion. Carcinogenesis (2009) 0.94
The endothelial cell-produced antiangiogenic cytokine vascular endothelial growth inhibitor induces dendritic cell maturation. J Immunol (2007) 0.94
Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus. Am J Clin Pathol (2005) 0.93
Lupeol, a dietary triterpene, inhibited growth, and induced apoptosis through down-regulation of DR3 in SMMC7721 cells. Cancer Invest (2009) 0.93
Selectin antagonists : therapeutic potential in asthma and COPD. Treat Respir Med (2005) 0.92
Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma. J Cancer Res Clin Oncol (2001) 0.91
Amadori-modified glycated albumin predominantly induces E-selectin expression on human umbilical vein endothelial cells through NADPH oxidase activation. Clin Chim Acta (2006) 0.91
Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients. Angiogenesis (2006) 0.90
The involvement of selectins and their ligands in tumor-progression. Immunol Lett (2005) 0.90
Correlation between expression of DcR3 on tumor cells and sensitivity to FasL. Cell Mol Immunol (2007) 0.90
Targeting tumors with LIGHT to generate metastasis-clearing immunity. Cytokine Growth Factor Rev (2008) 0.87
Regulation of the metastatic process by E-selectin and stress-activated protein kinase-2/p38. Ann N Y Acad Sci (2002) 0.87
Expression of Apo-3 and Apo-3L in primitive neuroectodermal tumours of the central and peripheral nervous system. Eur J Cancer (2002) 0.87
CD95 ligand expression as a mechanism of immune escape in breast cancer. Immunology (2000) 0.86
Decoy receptor 3 (DcR3) is proteolytically processed to a metabolic fragment having differential activities against Fas ligand and LIGHT. Biochem Pharmacol (2003) 0.85
Soluble receptor (DcR3) and cellular inhibitor of apoptosis-2 (cIAP-2) protect human cytotrophoblast cells against LIGHT-mediated apoptosis. Am J Pathol (2004) 0.85
Creation of a LIGHT mutant with the capacity to evade the decoy receptor for cancer therapy. Biomaterials (2010) 0.84
Tumor-microenvironment interactions: the selectin-selectin ligand axis in tumor-endothelium cross talk. Cancer Treat Res (2006) 0.84
Characterization of cis-regulatory elements of the vascular endothelial growth inhibitor gene promoter. Biochem J (2005) 0.84
Immunomodulatory effect of decoy receptor 3 on the differentiation and function of bone marrow-derived dendritic cells in nonobese diabetic mice: from regulatory mechanism to clinical implication. J Leukoc Biol (2003) 0.84
[Relationship between expression of decoy receptor 3 and apoptosis in hepatocellular carcinoma]. Zhonghua Bing Li Xue Za Zhi (2007) 0.83
Targeting selectins for the treatment of respiratory diseases. Curr Opin Investig Drugs (2001) 0.82
Adhesion and lymphocyte costimulatory molecules in systemic rheumatic diseases. Clin Rheumatol (1999) 0.80
PSGL-1 as a novel therapeutic target. Drug News Perspect (2004) 0.79
Therapeutic potential of selectin antagonists in psoriasis. Expert Opin Investig Drugs (2006) 0.76
[Preparation and identification of monoclonal antibodies against human DcR3]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi (2008) 0.76
[Clinical significance and correlation between elevated serum TR6 and lympho-metastasis in gastric cancer]. Zhonghua Wai Ke Za Zhi (2003) 0.75
[Expression of DcR3 protein and its significance in laryngeal carcinoma]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2007) 0.75
Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann Surg Oncol (2005) 3.30
PALB2 links BRCA1 and BRCA2 in the DNA-damage response. Curr Biol (2009) 3.15
454 pyrosequencing reveals bacterial diversity of activated sludge from 14 sewage treatment plants. ISME J (2011) 2.32
Loss of tight junction barrier function and its role in cancer metastasis. Biochim Biophys Acta (2008) 1.95
Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J Biol Chem (2005) 1.90
The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res (2004) 1.80
Endogenous bone morphogenetic protein-7 controls the motility of prostate cancer cells through regulation of bone morphogenetic protein antagonists. J Urol (2007) 1.73
Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Res (2005) 1.66
RNF8-dependent histone modifications regulate nucleosome removal during spermatogenesis. Dev Cell (2010) 1.57
The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol (2003) 1.51
Histone ubiquitination associates with BRCA1-dependent DNA damage response. Mol Cell Biol (2008) 1.50
Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids (2005) 1.46
Metastasis suppressor 1 (MTSS1) demonstrates prognostic value and anti-metastatic properties in breast cancer. Eur J Cancer (2009) 1.45
Plasmid metagenome reveals high levels of antibiotic resistance genes and mobile genetic elements in activated sludge. PLoS One (2011) 1.41
Is N-cadherin expression important in ductal carcinoma? South Med J (2008) 1.37
Levels of expression of endothelial markers specific to tumour-associated endothelial cells and their correlation with prognosis in patients with breast cancer. Clin Exp Metastasis (2004) 1.37
Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator. Breast Cancer Res (2004) 1.35
Expression of transcription factor CREB1 in human breast cancer and its correlation with prognosis. Oncol Rep (2007) 1.34
Loss of tight junction plaque molecules in breast cancer tissues is associated with a poor prognosis in patients with breast cancer. Eur J Cancer (2004) 1.34
The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer. Int J Oncol (2008) 1.32
Polo-like kinase 1 is essential for early embryonic development and tumor suppression. Mol Cell Biol (2008) 1.29
Biased diversity metrics revealed by bacterial 16S pyrotags derived from different primer sets. PLoS One (2013) 1.27
The elevated level of CXCR4 is correlated with nodal metastasis of human breast cancer. Breast (2005) 1.24
Placenta growth factor is over-expressed and has prognostic value in human breast cancer. Eur J Cancer (2005) 1.24
Activation of vascular endothelial growth factor receptor-1 sustains angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-kinase pathway in endothelial cells. Diabetes (2003) 1.20
Aurora A is essential for early embryonic development and tumor suppression. J Biol Chem (2008) 1.17
Vascular endothelial growth factor-induced endothelial cell proliferation is regulated by interaction between VEGFR-2, SH-PTP1 and eNOS. Microvasc Res (2005) 1.16
Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer. Anticancer Res (2011) 1.15
Higher expression levels of SOCS 1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human breast cancer. BMC Cancer (2010) 1.15
KiSS-1 expression in human breast cancer. Clin Exp Metastasis (2005) 1.14
Formation of a polypseudorotaxane via self-assembly of γ-cyclodextrin with poly(N-isopropylacrylamide). Macromol Rapid Commun (2012) 1.14
Differential expression of the CCN family member WISP-1, WISP-2 and WISP-3 in human colorectal cancer and the prognostic implications. Int J Oncol (2010) 1.14
Database and analyses of known alternatively spliced genes in plants. Genomics (2003) 1.13
Differential expression and prognostic implications of the CCN family members WISP-1, WISP-2, and WISP-3 in human breast cancer. Ann Surg Oncol (2007) 1.12
The Claudin family and its role in cancer and metastasis. Front Biosci (Landmark Ed) (2011) 1.12
NUPR1 interacts with p53, transcriptionally regulates p21 and rescues breast epithelial cells from doxorubicin-induced genotoxic stress. Curr Cancer Drug Targets (2008) 1.11
Quantitative structure-activity relationship modeling of rat acute toxicity by oral exposure. Chem Res Toxicol (2009) 1.11
The molecular and clinical impact of hepatocyte growth factor, its receptor, activators, and inhibitors in wound healing. Wound Repair Regen (2006) 1.10
Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4. Mol Cancer Res (2008) 1.07
Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome. Mol Cancer (2008) 1.07
PBmice: an integrated database system of piggyBac (PB) insertional mutations and their characterizations in mice. Nucleic Acids Res (2007) 1.07
Tight junctions in cancer metastasis. Front Biosci (Landmark Ed) (2011) 1.07
Correction of the sickle cell mutation in embryonic stem cells. Proc Natl Acad Sci U S A (2006) 1.06
WAVE3 is associated with invasiveness in prostate cancer cells. Urol Oncol (2009) 1.06
Bone metastasis in prostate cancer: molecular and cellular mechanisms (Review). Int J Mol Med (2007) 1.06
MTSS1: a multifunctional protein and its role in cancer invasion and metastasis. Front Biosci (Schol Ed) (2011) 1.05
Pomegranate (Punica granatum) pure chemicals show possible synergistic inhibition of human PC-3 prostate cancer cell invasion across Matrigel. Invest New Drugs (2005) 1.05
The Kiss-1/Kiss-1R complex as a negative regulator of cell motility and cancer metastasis (Review). Int J Mol Med (2013) 1.04
An interlaboratory-verified method for the determination of vitamins A and E in milk- and soy-based infant formula by liquid chromatography with matrix solid-phase dispersion extraction. J AOAC Int (2004) 1.04
KAI-1/CD82, the molecule and clinical implication in cancer and cancer metastasis. Histol Histopathol (2009) 1.03
Decreased pigment epithelium-derived factor expression in human breast cancer progression. Clin Cancer Res (2006) 1.03
Expression of Placenta growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance. World J Surg Oncol (2005) 1.03
Bone morphogenetic proteins in development and progression of breast cancer and therapeutic potential (review). Int J Mol Med (2009) 1.03
Brain-derived neurotrophic factor expression predicts adverse pathological & clinical outcomes in human breast cancer. Cancer Cell Int (2011) 1.02
iASPP is over-expressed in human non-small cell lung cancer and regulates the proliferation of lung cancer cells through a p53 associated pathway. BMC Cancer (2010) 1.02
Expression of interleukin 11 and its receptor and their prognostic value in human breast cancer. Ann Surg Oncol (2006) 1.01
Upregulation of tumour endothelial marker-8 by interleukin-1beta and its impact in IL-1beta induced angiogenesis. Int J Mol Med (2004) 1.01
Metagenomic analysis on seasonal microbial variations of activated sludge from a full-scale wastewater treatment plant over 4 years. Environ Microbiol Rep (2013) 1.01
Placenta growth factor-1 exerts time-dependent stabilization of adherens junctions following VEGF-induced vascular permeability. PLoS One (2011) 1.00
Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer. Anticancer Res (2013) 1.00
Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells. Int J Cancer (2006) 0.99
Loss of occludin leads to the progression of human breast cancer. Int J Mol Med (2010) 0.99
Biphasic effects of 17-beta-estradiol on expression of occludin and transendothelial resistance and paracellular permeability in human vascular endothelial cells. J Cell Physiol (2003) 0.98
Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist. Carcinogenesis (2003) 0.98
Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development. J Med Chem (2014) 0.98
Cell adhesion molecules and adhesion abnormalities in prostate cancer. Crit Rev Oncol Hematol (2002) 0.98
Solvent- and thermoresponsive polyrotaxanes with beta-cyclodextrin dispersed/aggregated structures on a pluronic F127 backbone. J Phys Chem B (2010) 0.97
The expression of gene transcripts of telomere-associated genes in human breast cancer: correlation with clinico-pathological parameters and clinical outcome. Breast Cancer Res Treat (2007) 0.97
The expression and prognostic value of the guanine nucleotide exchange factors (GEFs) Trio, Vav1 and TIAM-1 in human breast cancer. Int Semin Surg Oncol (2008) 0.97
Anti-cancer ProTides: tuning the activity of BVDU phosphoramidates related to thymectacin. Bioorg Med Chem (2005) 0.97
Electrophysiological evidence of heterogeneity in visual statistical learning in young children with ASD. Dev Sci (2014) 0.96
N-WASP is a putative tumour suppressor in breast cancer cells, in vitro and in vivo, and is associated with clinical outcome in patients with breast cancer. Clin Exp Metastasis (2007) 0.96
The localisation and reduction of nuclear staining of PPARgamma and PGC-1 in human breast cancer. Oncol Rep (2004) 0.96
αB-crystallin, an effector of unfolded protein response, confers anti-VEGF resistance to breast cancer via maintenance of intracrine VEGF in endothelial cells. Mol Cancer Res (2011) 0.95
Diversity and quantity of ammonia-oxidizing Archaea and Bacteria in sediment of the Pearl River Estuary, China. Appl Microbiol Biotechnol (2011) 0.95
Gene identification and expression analysis of 86,136 Expressed Sequence Tags (EST) from the rice genome. Genomics Proteomics Bioinformatics (2003) 0.95
The impact of Metastasis Suppressor-1, MTSS1, on oesophageal squamous cell carcinoma and its clinical significance. J Transl Med (2011) 0.94
Expression of the prostate transglutaminase (TGase-4) in prostate cancer cells and its impact on the invasiveness of prostate cancer. J Exp Ther Oncol (2007) 0.94
Deregulation of cofactor of BRCA1 expression in breast cancer cells. J Cell Biochem (2008) 0.94
Expression of pigment epithelial derived factor is reduced in non-small cell lung cancer and is linked to clinical outcome. Int J Mol Med (2006) 0.94
Shape-dependent acidity and photocatalytic activity of Nb2O5 nanocrystals with an active TT (001) surface. Angew Chem Int Ed Engl (2012) 0.94
Claudin-5 is involved in breast cancer cell motility through the N-WASP and ROCK signalling pathways. J Exp Clin Cancer Res (2012) 0.94
Genetic manipulation of stromal cell-derived factor-1 attests the pivotal role of the autocrine SDF-1-CXCR4 pathway in the aggressiveness of breast cancer cells. Int J Oncol (2005) 0.93
Protective effects of sitagliptin on myocardial injury and cardiac function in an ischemia/reperfusion rat model. Eur J Pharmacol (2013) 0.93
Type II transmembrane serine protease (TTSP) deregulation in cancer. Front Biosci (Landmark Ed) (2011) 0.93
Bone morphogenetic protein and bone metastasis, implication and therapeutic potential. Front Biosci (Landmark Ed) (2011) 0.93
A novel two-step hierarchical quantitative structure-activity relationship modeling work flow for predicting acute toxicity of chemicals in rodents. Environ Health Perspect (2009) 0.93
HuR, a key post-transcriptional regulator, and its implication in progression of breast cancer. Histol Histopathol (2010) 0.93
Surgical management and prognostic factors of hilar cholangiocarcinoma: experience with 115 cases in China. Ann Surg Oncol (2008) 0.93
Expression of the cell to cell adhesion molecule, ALCAM, in breast cancer patients and the potential link with skeletal metastasis. Oncol Rep (2008) 0.93